These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 26200058)

  • 1. Neuroinflammation in the pathophysiology of Parkinson's disease and therapeutic evidence of anti-inflammatory drugs.
    Bassani TB; Vital MA; Rauh LK
    Arq Neuropsiquiatr; 2015 Jul; 73(7):616-23. PubMed ID: 26200058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Common anti-inflammatory drugs are potentially therapeutic for Parkinson's disease?
    Asanuma M; Miyazaki I
    Exp Neurol; 2007 Aug; 206(2):172-8. PubMed ID: 17599833
    [No Abstract]   [Full Text] [Related]  

  • 4. Neuroinflammation in Parkinson's disease.
    Hirsch EC; Vyas S; Hunot S
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S210-2. PubMed ID: 22166438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are Dopamine Oxidation Metabolites Involved in the Loss of Dopaminergic Neurons in the Nigrostriatal System in Parkinson's Disease?
    Herrera A; Muñoz P; Steinbusch HWM; Segura-Aguilar J
    ACS Chem Neurosci; 2017 Apr; 8(4):702-711. PubMed ID: 28233992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention.
    Tansey MG; Goldberg MS
    Neurobiol Dis; 2010 Mar; 37(3):510-8. PubMed ID: 19913097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration.
    Morale MC; Serra PA; L'episcopo F; Tirolo C; Caniglia S; Testa N; Gennuso F; Giaquinta G; Rocchitta G; Desole MS; Miele E; Marchetti B
    Neuroscience; 2006; 138(3):869-78. PubMed ID: 16337092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CNI-1493 attenuates neuroinflammation and dopaminergic neurodegeneration in the acute MPTP mouse model of Parkinson's disease.
    Noelker C; Stuckenholz V; Reese JP; Alvarez-Fischer D; Sankowski R; Rausch T; Oertel WH; Hartmann A; van Patten S; Al-Abed Y; Bacher M
    Neurodegener Dis; 2013; 12(2):103-10. PubMed ID: 23147695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms.
    Prediger RD
    J Alzheimers Dis; 2010; 20 Suppl 1():S205-20. PubMed ID: 20182024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-steroidal anti-inflammatory drugs in Parkinson's disease.
    Esposito E; Di Matteo V; Benigno A; Pierucci M; Crescimanno G; Di Giovanni G
    Exp Neurol; 2007 Jun; 205(2):295-312. PubMed ID: 17433296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammation in Parkinson's disease.
    Tufekci KU; Meuwissen R; Genc S; Genc K
    Adv Protein Chem Struct Biol; 2012; 88():69-132. PubMed ID: 22814707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroinflammation in Parkinson's disease: a target for neuroprotection?
    Hirsch EC; Hunot S
    Lancet Neurol; 2009 Apr; 8(4):382-97. PubMed ID: 19296921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroinflammation - A major cause for striatal dopaminergic degeneration in Parkinson's disease.
    Kaur K; Gill JS; Bansal PK; Deshmukh R
    J Neurol Sci; 2017 Oct; 381():308-314. PubMed ID: 28991704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Src tyrosine kinase activity by squamosamide derivative FLZ attenuates neuroinflammation in both in vivo and in vitro Parkinson's disease models.
    Tai W; Ye X; Bao X; Zhao B; Wang X; Zhang D
    Neuropharmacology; 2013 Dec; 75():201-12. PubMed ID: 23916477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of microglia on the pathogenesis of Parkinson's disease.
    Long-Smith CM; Sullivan AM; Nolan YM
    Prog Neurobiol; 2009 Nov; 89(3):277-87. PubMed ID: 19686799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An inflammatory pathomechanism for Parkinson's disease?
    Wersinger C; Sidhu A
    Curr Med Chem; 2006; 13(5):591-602. PubMed ID: 16515523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights into Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based Therapies.
    Rocha NP; de Miranda AS; Teixeira AL
    Biomed Res Int; 2015; 2015():628192. PubMed ID: 26295044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic approaches to inflammation in neurodegenerative disease.
    Klegeris A; McGeer EG; McGeer PL
    Curr Opin Neurol; 2007 Jun; 20(3):351-7. PubMed ID: 17495632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata.
    Hardman CD; Halliday GM; McRitchie DA; Cartwright HR; Morris JG
    Exp Neurol; 1997 Mar; 144(1):183-92. PubMed ID: 9126169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Death in the substantia nigra: a motor tragedy.
    Esposito E; Di Matteo V; Di Giovanni G
    Expert Rev Neurother; 2007 Jun; 7(6):677-97. PubMed ID: 17563251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.